WO2008029168A3 - Treatment of duchenne muscular dystrophy - Google Patents

Treatment of duchenne muscular dystrophy Download PDF

Info

Publication number
WO2008029168A3
WO2008029168A3 PCT/GB2007/003403 GB2007003403W WO2008029168A3 WO 2008029168 A3 WO2008029168 A3 WO 2008029168A3 GB 2007003403 W GB2007003403 W GB 2007003403W WO 2008029168 A3 WO2008029168 A3 WO 2008029168A3
Authority
WO
WIPO (PCT)
Prior art keywords
muscular dystrophy
duchenne muscular
treatment
represent
different
Prior art date
Application number
PCT/GB2007/003403
Other languages
French (fr)
Other versions
WO2008029168A2 (en
Inventor
Graham Michael Wynne
Stephen Paul Wren
Cristine Lecci
Original Assignee
Summit Corp Plc
Graham Michael Wynne
Stephen Paul Wren
Cristine Lecci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0617740A external-priority patent/GB0617740D0/en
Priority claimed from GB0619283A external-priority patent/GB0619283D0/en
Application filed by Summit Corp Plc, Graham Michael Wynne, Stephen Paul Wren, Cristine Lecci filed Critical Summit Corp Plc
Publication of WO2008029168A2 publication Critical patent/WO2008029168A2/en
Publication of WO2008029168A3 publication Critical patent/WO2008029168A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/16—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4

Abstract

There are discloses compounds of formula I wherein A1, A2, A3 and A4, which may be the same or different, represent N or CR1, X, Y and Z, which may be the same or different, represent O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, R1, R4, R5, R6, R7, R20 are according to the present specification, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.
PCT/GB2007/003403 2006-09-08 2007-09-07 Treatment of duchenne muscular dystrophy WO2008029168A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0617740.6 2006-09-08
GB0617740A GB0617740D0 (en) 2006-09-08 2006-09-08 Treatment of duchenne muscular dystrophy
GB0619283.5 2006-09-29
GB0619283A GB0619283D0 (en) 2006-09-29 2006-09-29 Treatment of duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
WO2008029168A2 WO2008029168A2 (en) 2008-03-13
WO2008029168A3 true WO2008029168A3 (en) 2008-05-02

Family

ID=39048876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/003403 WO2008029168A2 (en) 2006-09-08 2007-09-07 Treatment of duchenne muscular dystrophy

Country Status (1)

Country Link
WO (1) WO2008029168A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
GB0715938D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
CN102159622A (en) 2008-09-23 2011-08-17 聂克斯姆化学有限公司 Acetylenic polyamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
WO2011133751A2 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
PL3424534T3 (en) 2014-04-15 2021-11-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CN110225753B (en) * 2017-01-28 2022-12-09 金凯(辽宁)生命科技股份有限公司 Process for preparing 5-phenoxy-1 (3H) isobenzofuranones
CN111989325A (en) 2018-04-18 2020-11-24 星座制药公司 Modulators of methyl-modified enzymes, compositions and uses thereof
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005327A1 (en) * 1996-08-05 1998-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted aromatic compounds
US6180611B1 (en) * 1994-10-05 2001-01-30 Darwin Discovery, Ltd. Peptidyl compounds
WO2003087087A2 (en) * 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
DE102005018191A1 (en) * 2005-04-19 2006-10-26 Grünenthal GmbH Substituted cyclic urea derivatives and their use for the preparation of medicaments
WO2006122546A1 (en) * 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Non-peptidic inhibitors of akap/pka interaction

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180611B1 (en) * 1994-10-05 2001-01-30 Darwin Discovery, Ltd. Peptidyl compounds
WO1998005327A1 (en) * 1996-08-05 1998-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted aromatic compounds
WO2003087087A2 (en) * 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
DE102005018191A1 (en) * 2005-04-19 2006-10-26 Grünenthal GmbH Substituted cyclic urea derivatives and their use for the preparation of medicaments
WO2006122546A1 (en) * 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Non-peptidic inhibitors of akap/pka interaction

Also Published As

Publication number Publication date
WO2008029168A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
WO2008029168A3 (en) Treatment of duchenne muscular dystrophy
WO2008029152A3 (en) Treatment of duchenne muscular dystrophy
WO2008142055A3 (en) Antiviral agents
WO2007091106A3 (en) Treatment of duchenne muscular dystrophy
WO2007010273A3 (en) Use of thiazole derivatives and analogues in the treatment of cancer
MX2009006742A (en) Novel compounds.
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
WO2008142720A3 (en) Quinazolin-oxime derivatives as hsp90 inhibitors
WO2010084115A3 (en) Antiviral agents
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
WO2008126034A3 (en) Oxazolidinone antibiotics
WO2007029029A3 (en) Tetracyclic indole derivatives as antiviral agents
MX2010009163A (en) Heterocyclic urea derivatives and methods of use thereof-211.
HK1108703A1 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
WO2006046039A3 (en) Tetracyclic indole derivatives as antiviral agents
MX2013001989A (en) Composition containing tetracyclic compound.
MXPA05010945A (en) Heteroaromatic pentacyclic compound and medicinal use thereof.
WO2006095159A8 (en) (imidazolo-5-yl)-2-anilo-pyrimidines as agents for the inhibition of cell proliferation
WO2008116813A3 (en) Combination medicaments for treating bacterial infections
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
EP2039686A4 (en) Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases
WO2008064218A3 (en) Amido anti-viral compounds
GB0413087D0 (en) Therapeutic compounds
WO2008069917A3 (en) Novel cyclic peptides
MX2010013310A (en) Heterocyclic urea derivatives for the treatment of bacterial infections.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804201

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07804201

Country of ref document: EP

Kind code of ref document: A2